Led by Battery Ventures, the round will scale Triomics' AI platform across cancer centers nationwide and deepen life-sciences partnerships

由Battery Ventures领投，此轮融资将把Triomics的AI平台扩展到全国的癌症中心，并加深与生命科学领域的合作伙伴关系。

NEW YORK

纽约

,

，

May 28, 2026

2026年5月28日

/PRNewswire/ --

/PRNewswire/ --

Triomics

三组学

, an oncology AI company helping cancer centers operationalize complex clinical information, today announced it has raised $22 million in Series B financing led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly-owned subsidiary of Texas Oncology.

，一家帮助癌症中心实现复杂临床信息操作的肿瘤学AI公司，今天宣布已完成2200万美元的B轮融资。本轮融资由Battery Ventures领投，现有投资者Nexus Venture Partners、Lightspeed和Y Combinator参与，战略支持者包括Oncology Ventures以及德克萨斯肿瘤学全资子公司Precision Health Informatics。

This round brings Triomics' total funding raised to date to more than $36 million..

本轮融资使 Triomics 迄今为止的总融资额超过 3600 万美元。

The new capital will be used to accelerate adoption across health systems, oncology networks and life sciences organizations; grow Triomics' AI/engineering and forward-deployed teams; and advance the company's AI agents for clinical care and research. Triomics is already working with leading cancer centers like Memorial Sloan Kettering Cancer Center (MSK), MD Anderson, Yale Cancer Center and its partner Smilow Cancer Hospital, and Mount Sinai Tisch Cancer Center, as well as some of the nation's largest community oncology practices, such as Texas Oncology..

新资金将用于加速在卫生系统、肿瘤网络和生命科学组织中的应用；扩大 Triomics 的人工智能/工程和前沿部署团队；并推进公司用于临床护理和研究的人工智能代理。Triomics 已经与一些领先的癌症中心展开合作，如纪念斯隆凯特琳癌症中心（MSK）、MD安德森癌症中心、耶鲁癌症中心及其合作伙伴斯米洛癌症医院，以及西奈山蒂施癌症中心，还有一些美国最大的社区肿瘤实践机构，如德克萨斯肿瘤学。

'Oncology faces an information burden at a scale legacy systems were never designed to handle, and that burden can stand in the way of better outcomes,' said Sarim Khan, co-founder and CEO of Triomics. 'Clinicians, research coordinators and medical assistants are working against records that have become too large and too dynamic to process manually.

“肿瘤学面临着传统系统从未设计来处理的规模的信息负担，而这种负担可能会阻碍更好的治疗结果，”Triomics的联合创始人兼首席执行官Sarim Khan说道。“临床医生、研究协调员和医疗助理正在应对变得过于庞大和动态以至于无法手动处理的记录。”

We built Triomics to turn that complexity into usable intelligence inside the workflow, purpose-built for oncology. This financing allows us to bring that infrastructure to many more cancer centers and improve care for cancer patients.'.

我们构建了 Triomics，以将这种复杂性转化为工作流程中的可用信息，专为肿瘤学设计。这笔资金使我们能够将这一基础设施扩展到更多的癌症中心，并改善癌症患者的治疗。

Beyond provider workflows, Triomics has built a broader oncology network that helps life- sciences organizations with their critical clinical-trial operations. The company believes the combination of deep provider workflow integration across cancer centers, combined with oncology-specific AI infrastructure, creates a durable foundation for the next generation of care and research applications..

除了供应商工作流程之外，Triomics还建立了一个更广泛的肿瘤学网络，帮助生命科学组织进行关键的临床试验操作。该公司认为，将跨癌症中心的深度供应商工作流程整合与肿瘤学特定的人工智能基础设施相结合，为下一代护理和研究应用创造了持久的基础。

Transforming Oncology's Data Overload into Actionable Intelligence

将肿瘤学的数据过载转化为可操作的情报

Cancer care is no longer constrained by a lack of information; it's limited by the ability to use the data that already exists. A single patient history can span hundreds of narrative-heavy clinic notes, pathology and radiology reports, biomarker results, outside records, prior treatments, and ever-evolving trial criteria and guidelines.

癌症治疗不再受限于信息的缺乏；而是受制于利用已有数据的能力。单个患者的病史可能涵盖数百份叙述繁多的临床记录、病理和影像报告、生物标志物结果、外部记录、既往治疗，以及不断演变的试验标准和指南。

Yet the workflows required to make that information usable have remained overwhelmingly manual..

然而，要使这些信息可用所需的工作流程仍然绝大多数是手动的。

'Oncology is the hardest place to build AI, yet the most important,' said Hrituraj Singh, co-founder and CTO of Triomics. 'Getting a model to reason reliably across thousands of pages of notes, pathology, imaging and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use.

“肿瘤学是构建人工智能最困难的领域，但也是最重要的领域，”Triomics联合创始人兼首席技术官Hrituraj Singh表示。“让一个模型能够可靠地处理数千页的病历、病理、影像和不断变化的试验标准，并展示其工作过程，这是区分演示版和临床医生实际使用的软件的关键所在。”

We've spent four years building that foundation and this round lets us push even further.'.

我们花了四年时间打下基础，这一轮融资让我们能够更进一步。

Founded in 2021 by Khan and Singh, Triomics is building a platform that uses AI agents to read the full longitudinal patient record and converts unstructured information into structured, explainable outputs. Then, it delivers those insights directly into clinical and operational workflows. Unlike lightweight summarization tools, every output is source-backed and verifiable inside the clinician's workflow.

Triomics由Khan和Singh于2021年创立，正在构建一个平台，利用AI代理阅读患者的完整纵向记录，并将非结构化信息转化为结构化、可解释的输出。随后，它将这些洞察直接传递到临床和操作工作流程中。与轻量级总结工具不同，每个输出都有来源支持，并可在临床医生的工作流程中验证。

The platform supports proactive clinical trial matching, pre-visit chart review and preparation, and oncology data abstraction for registry, quality improvement and operational use cases..

该平台支持主动的临床试验匹配、就诊前的病历审查与准备，以及用于登记、质量改进和操作用例的肿瘤学数据提取。

Cancer centers rely on Triomics to expand trial access, reduce the burden of manual chart review, improve visit preparation and generate higher‑quality structured data for research and operations. Published results show that users of the company's product have

癌症中心依靠Triomics来扩大试验的可及性，减轻人工图表审查的负担，改善就诊准备，并为研究和运营生成更高质量的结构化数据。已发布的结果显示，该公司产品的用户具有

increased trial matches by 40%

将试验比赛增加了40%

and

和

trial enrollments by more than 30%, while also reducing chart review times by 67%

试验注册人数增加了30%以上，同时将图表审查时间减少了67%。

. The platform has received peer-review validation in

该平台已收到同行评审的验证

Nature Digital Medicine

自然数字医学

and was presented at

并在以下场合展示

ASCO

美国临床肿瘤学会

, underscoring growing demand for AI that can operate reliably on the full patient record.

，强调了对能够可靠地操作完整患者记录的人工智能的需求不断增长。

'We are excited to partner with Triomics, our selected solution for oncology clinical trial matching, to extend our collaboration to an AI-enabled method for cancer registry abstraction and reporting. This activity is labor intensive, subjective and challenging to complete in a timely manner. Our goal is to produce autonomous chart abstraction of clinical registry quality that can be rapidly reviewed and finalized for reporting by human registrars to comply with mandatory state, federal and professional society reporting obligations,' said Lee Schwamm, MD, chief digital health officer, Yale New Haven Health System, and associate dean, Digital Strategy & Transformation, Yale School of Medicine..

“我们很高兴与Triomics合作，这是我们为肿瘤临床试验匹配所选择的解决方案，并将我们的合作扩展到一种用于癌症登记摘要和报告的人工智能方法。这项工作劳动强度大、主观性强，并且难以及时完成。我们的目标是生成自主的临床登记质量图表摘要，供人工登记员快速审查和定稿，以满足强制性的州、联邦和专业学会报告要求，”耶鲁纽黑文卫生系统首席数字健康官、耶鲁医学院数字战略与转型副院长Lee Schwamm博士表示。

'Triomics built what oncology has always needed: AI infrastructure that actually works on the full patient record,' said Brandon Gleklen, principal at Battery Ventures, who is joining the Triomics board of directors. 'We are live at some of the top cancer centers and demonstrating measurable outcomes—faster enrollment, less manual chart review—and the same underlying AI infrastructure already powers multiple distinct workflows with no redundant integrations.

“Triomics构建了肿瘤学一直以来所需要的：一个真正能够在完整患者记录上运作的AI基础设施，”Battery Ventures的负责人布兰登·格莱克伦说道，他将加入Triomics董事会。“我们已经在一些顶级癌症中心投入使用，并展示了可衡量的成果——更快的患者入组、更少的手动病历审查——同样的底层AI基础设施已经支持多个不同的工作流程，且无需重复集成。”

That kind of platform leverage, inside a customer base this strong, is rare at this stage.'.

在这种强大的客户群中，这种平台杠杆作用在这个阶段是很少见的。

About Triomics

关于Triomics

Triomics is an oncology AI company building the infrastructure that turns complex, longitudinal cancer records into structured, explainable intelligence. The company's platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction, helping care teams, research teams, and health systems act faster on the information already in the chart.

Triomics是一家肿瘤学AI公司，致力于构建将复杂、纵向的癌症记录转化为结构化、可解释情报的基础设施。该公司平台支持患者试验匹配、就诊前图表准备和肿瘤数据提取，帮助护理团队、研究团队和卫生系统更快地利用已有图表中的信息采取行动。

Headquartered in New York, Triomics is backed by Battery Ventures, Lightspeed, Nexus Venture Partners, Y Combinator and Oncology Ventures. For more information, visit .

总部位于纽约的 Triomics 得到了 Battery Ventures、Lightspeed、Nexus Venture Partners、Y Combinator 和 Oncology Ventures 的支持。欲了解更多信息，请访问 。

www.triomics.com

www.triomics.com

.

。

SOURCE Triomics

来源：Triomics

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示